RE:Theralase is a high risk/high reward play, says Mackie"On the company and stock, Uddin wrote, “Besides TLD-1433, TLT plans to commence pre-clinical toxicology studies with an i.v. formulation of TLD-1433 combined with transferrin (termed Rutherrin), which could potentially be activated by radiation to treat other types of tumors (glioblastoma and NSCLC)."
Tox studies not started yet? This is disappointing. They better push the NMIBC study hard so they can start selling something within a year or two.